Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma
Year: 2021
Type: article
Authors: John Kirkwood, Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Vanna Sileni, James Larkin, Marta Nyakas, Andrew Haydon, Caroline Dutriaux, Jacob Schachter, Caroline Robert, Laurent Mortier, Hiya Banerjee, Tomas Haas, Monique Tan, Mike Lau, Dirk Schadendorf, Georgina Long, Mario Mandala
Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University Hospital Zurich, University Hospital Schleswig-Holstein, Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Queensland, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, Istituto Oncologico Veneto, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Oslo University Hospital, The Alfred Hospital, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Tel Aviv University, Sheba Medical Center, Institut Gustave Roussy, Inserm, Université de Lille, Novartis (Switzerland), Novartis (United States), Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, The University of Sydney, Melanoma Institute Australia, Ospedale Papa Giovanni XXIII
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W3119124806